J&J Medical Connect
Oncology
Oncology

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Multiple myeloma

Treatment / Treatment options and MOAs

Treatment selection considerations Treatment approach Autologous stem cell transplant Post-transplant treatment CAR-T therapy Treatment options and MOAs IMWG sequencing recommendations Protein targets Treatment considerations

Treatment options and MOAs

Treatment choices for MM include several classes of therapies with different MOAs, many of which can be used as single agents or in combination1

Treatment class MOA
Proteasome inhibitors (PIs)1
  • Interfere with the degradation of proteins within the cells
  • Myeloma cells are sensitive to this inhibition
Immunomodulatory drugs1
  • Possess multiple antimyeloma properties including immune modulation, antiangiogenic, anti-inflammatory, and antiproliferative effects
Monoclonal antibodies (mAbs)1
  • Target specific proteins on myeloma cells, which may activate immune responses
Corticosteroids2
  • Can cause apoptosis of myeloma cells
Chemotherapy3
  • An approach that targets dividing cells
Selective inhibitor of nuclear export (SINEs)4
  • Inhibits exportin-1 (XPO) resulting in activation of tumor suppressor proteins, glucocorticoid receptors, and immune response regulators, thereby inducing cell cycle arrest and apoptosis
Chimeric antigen receptor (CAR) T-cells5
  • T cells collected from a patient are genetically modified to express CARs, which can specifically recognize a targeted antigen
T-cell bispecific antibody6
  • Dual-binding affinity to tumor-associated antigens and CD3 T-cells promotes antitumor immunity within tumor tissue
Antibody drug conjugate7
  • mAbs chemically linked to cytotoxic drugs that selectively deliver a payload to cells expressing the target antigen

Triple-class refractory MM refers to disease specifically refractory to PIs, immunomodulatory drugs, and anti-CD38 mAbs8

MM, multiple myeloma; MOA, mechanism of action.

1. Cook G, et al. Crit Rev Oncol Hematol. 2018;121:74-89. 2. Pufall MA. Adv Exp Med Biol. 2015;872:315-33. 3. Siddik ZH. The Cancer Handbook. New York: John Wiley & Sons, Ltd; 2002. 4. Podar K, et al. Expert Opin Pharmacother. 2020;21(4):399-408. 5. Benmebarek M-R, et al. Int J Mol Sci. 2019;20(6):1283-1303. 6. Kamakura D, et al. Pharmaceuticals. 2021;14(11):1172-1195. 7. Khongorzul P, et al. Mol Cancer Res. 2020;18(1);3-19. 8. Stalker ME, Mark TM. Curr Oncol. 2022;29(7):4464-4477.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.